文献リスト

1) Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002; 123: 719-27

2) Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009; 137: 1680-6

3) Angus PW, Patterson SJ. Liver transplantation for hepatitis B: What is the best hepatitis B immune globulin/antiviral regimen？ Liver Transpl. 2008; 14: S15-22

4) Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007; 132: 931-7

5) Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation. 2007; 83: 231-3

6) Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl. 2008; 14: 435-42

7) Hussain M, Soldevia-Pico C, Emre S, et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl. 2006; 12: 253-8

8) Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation. 2007; 84: 650-4

9) Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci. 2007; 52: 2497-500

10) Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007; 13: 349-60

11) Borrotto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007; 47: 492-8

12) Qi X, Xiong S, Yang H, et al. In vitro susceptivility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007; 12: 355-62

13) Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007; 45: 307-13

14) Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007; 133: 1445-51

15) Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology. 2008; 48: 1460-6

16) Teperman L, Spivey J, Poordad F, et al. Emtricitabine/tenofovir combination＋/-HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment. J Hepatol. 2010; 52: S12-3

17) Lo CM, Liu CL, Chan SC, et al. Failure of HBV vaccination in patients receiving lamivudine pro-phylaxis after liver transplantation for CHB. J Hepatol. 2005; 43: 283-7

18) Gunther M, Neuhaus R, Bauer T, et al. Immunization with an adjuvant HBV vaccine in liver transplant recipients. Liver Transpl. 2006; 12: 316-9

19) Lo CM, Lau GK, Chan SC, et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for HBV. Am J Transplant. 2007; 7: 434-9

20) Gane E. Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low or no dose？ Liver Transpl. 2010; 16; S36-9

21) 日本肝移植研究会. 肝移植症例登録報告. 移植. 2009; 44: 559

22) Roche B, Samuel D. Hepatitis C virus: Up to the minute. Liver Transpl. 2010; 16: S26

23) Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2008; 8: 350

24) Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatictis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003; 9: 905

25) Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005; 42: 255

26) Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003; 39: 389

27) Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009; 50: 719

28) Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc. 2001; 33: 1355

29) Chalasani N, Manzabeitia C, Ferenci P, et al. Peg-interferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005; 41: 289

30) Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant. 2005; 5: 118

31) Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004; 78: 1308

32) Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006; 6: 1586

33) Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008; 49: 274

34) Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008; 15: 699

35) Navasa M, Casanovas T, Berenguer M, et al. Higher sustained virologic response and histologic improvement in recurrent hepatitis C after pegylated interferon plus ribavirin therapy under cyclosporine-based versus tacrolimus-based immunosuppressive therapy. J Hepatol. 2010; 52 (suppl 1): 24

36) Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl. 2009; 15: 738

37) Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma. Hepatology. 1999; 30; 1434

38) Herrero JI, Sangro B, Quiroga J, et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001; 7: 631

39) Hayashi PH, Ludkowski M, Forman LM, et al. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant. 2004; 4: 782

40) Maddala YK, Sradheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004; 10: 449

41) Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: impli-cations for the current organ allocation policy. Liver Transpl. 2003; 9: 684

42) Yamashiki N, Gaynor JJ, Kato T, et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant. 2004; 4: 774

43) Fisher RA, Maluf D, Cotterell AH, et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention to treat and dropout from liver transplant waiting list. Clin Transplant. 2004; 18: 504

44) Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004; 240: 900

45) Lu DSK, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005; 41: 1130

46) Martin AP, Goldstein RM, Dempster J, et al. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation-a clinical and histological examination. Clin Transplant. 2006; 20: 695

47) Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006; 12: 1260

48) Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007; 13: 272

49) Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pretransplant loco-regional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl. 2006; 12: 665

50) Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pre-trans-plantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2005; 11: 767

51) Pelletier SJ, Fu S, Thyagarajan V, et al. An intention to treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl. 2009; 15: 859

52) Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients chronic and malignant liver diseases. Am J Transplant. 2006; 6: 1416

53) Washburn K, Edwards E, Harper A, et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant. 2010; 10: 1652

54) Majno P, Mentha G, Toso C, for the geneva Liver cancer Study Group. Transplantation for hepatocellular carcinoma: management of patients on the waiting list. Liver Transpl. 2010; 16: S2

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp